Nden Ajeng Tresnawati, . (2022) PERBANDINGAN EFEKTIVITAS BIAYA TERAPI KOMBINASI OBAT METFORMIN-GLIMEPIRIDE DAN ACARBOSE-GLIMEPIRIDE DI RSUD SUMEDANG TAHUN 2021. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (177kB) |
|
Text
AWAL.pdf Download (1MB) |
|
Text
BAB I.pdf Download (210kB) |
|
Text
BAB II.pdf Restricted to Repository UPNVJ Only Download (892kB) |
|
Text
BAB III.pdf Restricted to Repository UPNVJ Only Download (392kB) |
|
Text
BAB IV.pdf Restricted to Repository UPNVJ Only Download (510kB) |
|
Text
BAB V.pdf Download (187kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (241kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository UPNVJ Only Download (307kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (72kB) |
|
Text
ARTIKEL KI.pdf Restricted to Repository staff only Download (405kB) |
Abstract
Type 2 Diabetes Mellitus (DM) is one of the cardiometabolic diseases with the highest prevalence worldwide, including Indonesia. The increasing number of type 2 diabetes mellitus is known to have become an economic burden on health sector in Indonesia. There are several options in the treatment of Type 2 DM either with monotherapy or combination of several drugs. At present, metformin, sulfonylurea, and acarbose have become common drugs in the treatment of Type 2 DM in Indonesia. Variations in antidiabetic drug therapy will cause differences in cost and effectiveness of therapy. The purpose of this study is to analyze the cost-effectiveness of the combination therapy of metformin-glimepiride and acarbose-glimepiride antidiabetic drugs in patients with Type 2 DM in the Outpatient Installation at RSUD Sumedang in 2021 based on the hospital's perspective. This study uses a cross-sectional design, data collection was carried out by documenting or recording medical record data and patient costs during the period of January-December 2021. A comparison of the effectiveness of therapy (∆GDS) and direct medical costs is carried out in the two groups. The results of the analysis showed that there was no significant difference in GDS in the combination of metformin-glimepiride and acarbose-glimepiride (mean difference 10.70 mg/dL-1; p-value = 0.457). The average total direct medical costs of the acarbose-glimepiride group was higher than that of the metformin-glimepiride group and there was a significant difference between the average costs of the antidiabetic drugs (p-value = 0.000). Based on the calculation of the cost-effectiveness results, the combination of metformin-glimepiride therapy is more cost effective than acarbose-glimepiride with an ACER value of metformin-glimepiride Rp.3.037,48. Keywords: Acarbose, cost effectiveness analysis, glimepiride, metfotmin, type 2 diabetes mellitus
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | [No.Panggil:1910211057] [Pembimbing 1: Hany Yusmaini] [Pembimbing 2: Mila Citrawati] [Penguji: Erna Harfiani] |
| Uncontrolled Keywords: | Acarbose, cost effectiveness analysis, glimepiride, metfotmin, type 2 diabetes mellitus |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Fakultas Kedokteran > Program Studi Kedokteran (S1) |
| Depositing User: | Nden Ajeng Tresnawati |
| Date Deposited: | 10 Mar 2023 07:46 |
| Last Modified: | 10 Mar 2023 07:46 |
| URI: | http://repository.upnvj.ac.id/id/eprint/22001 |
Actions (login required)
 |
View Item |